Cumberland Pharmaceuticals Inc (CPIX)
NASDAQ:CPIX
Want to see CPIX full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
―Last Year’s EPS
-0.05Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlights meaningful strategic progress: a transformational $100M acquisition agreement that unlocks near-term value, regulatory wins (expanded Caldolor label and facility clearance), commercialization progress (Talicia promotion, Vibativ China shipment) and an encouraging development pipeline (ifetroban with Fast Track and robust safety data). These positives are tempered by a modest Q1 revenue base, a GAAP net loss (~$3.3M) and limited cash on hand until the transaction closes, plus the company’s deliberate pivot away from pursuing double-digit revenue growth in 2026. On balance, the call emphasizes value realization and a clear strategic plan to focus on development, with the transaction expected to materially strengthen the balance sheet and reduce operating expense burden—leading to a favorable overall tone.Company Guidance
Transformational Strategic Transaction with Apotex
Apotex will acquire Cumberland's marketed U.S. commercial portfolio for $100 million in cash at closing, plus $9 million for inventory, transition service fees and a future sales-tied milestone — a transaction management expects will materially strengthen the balance sheet and unlock near-term shareholder value.
Revenue Performance and Product Mix
Combined Q1 2026 revenue from FDA-approved brands was $9.1 million (a 5% increase versus the comparable basis after excluding a $3 million one-time milestone in the prior year). Product-level Q1 revenue: Sancuso $2.9M, Vibativ $2.1M, Talicia $1.9M, Kristalose $1.0M and Caldolor $1.0M.
Pipeline Momentum — Ifetroban Clinical Progress
Ifetroban has been dosed in ~1,400 subjects with an outstanding safety database; positive Phase II top-line DMD results announced previously; FDA granted Fast Track designation for Duchenne muscular dystrophy and the program also holds orphan and rare pediatric disease designations. Ongoing trials include completed enrollment in systemic sclerosis and active enrollment in the idiopathic pulmonary fibrosis 'Fighting Fibrosis' Phase II trial (interim safety review found no new safety signals).
Regulatory and Commercial Advances for Branded Products
FDA approved expanded labeling for Caldolor to include postoperative pain (use in adults and pediatric patients 3 months+), FDA cleared the manufacturing facility enabling Vaprisol relaunch this year, and the first shipment of Vibativ to China occurred. Cumberland also launched national sales promotion for Talicia and updated Sancuso's website.
Positive Operating Cash Flow Despite Seasonal Quarter
Cumberland generated positive cash flow from operations of $387,000 in Q1 2026, reflecting improving cash generation from the recently acquired brands and ongoing commercialization efforts.
Balance Sheet and Tax Position
As of 3/31/2026 Cumberland reported $71M in total assets (including $11M cash), $49.7M in liabilities and $21.6M in shareholders' equity. Management cites >$53M in tax net operating loss carryforwards and a $30M tax basis in transaction assets, which is expected to limit transaction-related income taxes.
CPIX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CPIX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $4.55 | $4.37 | -3.96% |
Mar 03, 2026 | $4.58 | $3.67 | -19.87% |
Nov 04, 2025 | $2.66 | $2.33 | -12.41% |
Aug 05, 2025 | $3.79 | $3.21 | -15.30% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cumberland Pharmaceuticals Inc (CPIX) report earnings?
Cumberland Pharmaceuticals Inc (CPIX) is schdueled to report earning on Aug 11, 2026, After Close (Confirmed).
What is Cumberland Pharmaceuticals Inc (CPIX) earnings time?
Cumberland Pharmaceuticals Inc (CPIX) earnings time is at Aug 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CPIX EPS forecast?
Currently, no data Available